Compare NUVL & GBCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NUVL | GBCI |
|---|---|---|
| Founded | 2017 | 1955 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 6.3B |
| IPO Year | 2021 | 1996 |
| Metric | NUVL | GBCI |
|---|---|---|
| Price | $96.50 | $43.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 5 |
| Target Price | ★ $135.33 | $53.60 |
| AVG Volume (30 Days) | 449.1K | ★ 921.7K |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 3.04% |
| EPS Growth | N/A | ★ 18.45 |
| EPS | N/A | ★ 1.99 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $31.62 |
| Revenue Next Year | $1,165.56 | $8.37 |
| P/E Ratio | ★ N/A | $21.85 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $55.54 | $36.76 |
| 52 Week High | $113.02 | $53.99 |
| Indicator | NUVL | GBCI |
|---|---|---|
| Relative Strength Index (RSI) | 39.83 | 41.23 |
| Support Level | $73.71 | $43.81 |
| Resistance Level | $107.13 | $43.90 |
| Average True Range (ATR) | 3.10 | 1.03 |
| MACD | -0.09 | 0.20 |
| Stochastic Oscillator | 21.24 | 48.04 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Glacier Bancorp Inc is a regional bank holding company providing commercial banking services to scores of communities through its wholly-owned bank subsidiary, Glacier Bank. The bank operates a multitude of banking offices in Montana, Idaho, Colorado, Utah, Washington, and Wyoming. The bank's various products and services include deposit, loans, and mortgage origination services, among others. The bank predominantly serves individuals, small- to medium-sized businesses, community organizations, and public entities. Glacier emphasizes both internal growth and growth through selective acquisitions. A majority of the bank's loan portfolio is in commercial real estate, while a majority of its net revenue is net interest income.